TY - JOUR
T1 - Na+ Dysregulation Coupled with Ca2+ entry through NCX1 Promotes Muscular dystrophy in mice
AU - Burr, Adam R.
AU - Millay, Douglas P.
AU - Goonasekera, Sanjeewa A.
AU - Park, Ki Ho
AU - Sargent, Michelle A.
AU - Collins, James
AU - Altamirano, Francisco
AU - Philipson, Kenneth D.
AU - Allen, Paul D.
AU - Ma, Jianjie
AU - López, José Rafael
AU - Molkentina, Jeffery D.
PY - 2014/6
Y1 - 2014/6
N2 - Unregulated Ca2+ entry is thought to underlie muscular dystrophy. Here, we generated skeletal-muscle-specific transgenic (TG) mice expressing the Na+-Ca2+ exchanger 1 (NCX1) to model its identified augmentation during muscular dystrophy. The NCX1 transgene induced dystrophy-like disease in all hind-limb musculature, as well as exacerbated the muscle disease phenotypes in δ-sarcoglycan (Sgcd-/-), Dysf-/-, and mdx mouse models of muscular dystrophy. Antithetically, muscle-specific deletion of the Slc8a1 (NCX1) gene diminished hind-limb pathology in Sgcd-/- mice. Measured increases in baseline Na+ and Ca2+ in dystrophic muscle fibers of the hind-limb musculature predicts a net Ca2+ influx state due to reverse-mode operation of NCX1, which mediates disease. However, the opposite effect is observed in the diaphragm, where NCX1 overexpression mildly protects from dystrophic disease through a predicted enhancement in forward-mode NCX1 operation that reduces Ca2+ levels. Indeed, Atp1a2+/- (encoding Na+-K+ ATPase α2) mice, which have reduced Na+ clearance rates that would favor NCX1 reverse-mode operation, showed exacerbated disease in the hind limbs of NCX1 TG mice, similar to treatment with the Na+-K+ ATPase inhibitor digoxin. Treatment of Sgcd-/- mice with ranolazine, a broadly acting Na+ channel inhibitor that should increase NCX1 forward- mode operation, reduced muscular pathology.
AB - Unregulated Ca2+ entry is thought to underlie muscular dystrophy. Here, we generated skeletal-muscle-specific transgenic (TG) mice expressing the Na+-Ca2+ exchanger 1 (NCX1) to model its identified augmentation during muscular dystrophy. The NCX1 transgene induced dystrophy-like disease in all hind-limb musculature, as well as exacerbated the muscle disease phenotypes in δ-sarcoglycan (Sgcd-/-), Dysf-/-, and mdx mouse models of muscular dystrophy. Antithetically, muscle-specific deletion of the Slc8a1 (NCX1) gene diminished hind-limb pathology in Sgcd-/- mice. Measured increases in baseline Na+ and Ca2+ in dystrophic muscle fibers of the hind-limb musculature predicts a net Ca2+ influx state due to reverse-mode operation of NCX1, which mediates disease. However, the opposite effect is observed in the diaphragm, where NCX1 overexpression mildly protects from dystrophic disease through a predicted enhancement in forward-mode NCX1 operation that reduces Ca2+ levels. Indeed, Atp1a2+/- (encoding Na+-K+ ATPase α2) mice, which have reduced Na+ clearance rates that would favor NCX1 reverse-mode operation, showed exacerbated disease in the hind limbs of NCX1 TG mice, similar to treatment with the Na+-K+ ATPase inhibitor digoxin. Treatment of Sgcd-/- mice with ranolazine, a broadly acting Na+ channel inhibitor that should increase NCX1 forward- mode operation, reduced muscular pathology.
UR - http://www.scopus.com/inward/record.url?scp=84899834385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899834385&partnerID=8YFLogxK
U2 - 10.1128/MCB.00339-14
DO - 10.1128/MCB.00339-14
M3 - Article
C2 - 24662047
AN - SCOPUS:84899834385
SN - 0270-7306
VL - 34
SP - 1991
EP - 2002
JO - Molecular and Cellular Biology
JF - Molecular and Cellular Biology
IS - 11
ER -